---
title: MEDDEV 2.7/1 Rev 4 Under MDR: Is It Still Relevant in 2026?
description: MEDDEV 2.7/1 Rev 4 is legacy MDD guidance. Is it still useful under MDR in 2026? Here is the honest answer with concrete examples of what still applies.
authors: Tibor Zechmeister, Felix Lenhard
category: Clinical Evaluation & Investigations
primary_keyword: MEDDEV 2.7/1 rev 4 MDR
canonical_url: https://zechmeister-solutions.com/en/blog/meddev-271-rev4-mdr-relevance
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# MEDDEV 2.7/1 Rev 4 Under MDR: Is It Still Relevant in 2026?

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **MEDDEV 2.7/1 Rev 4 (June 2016) is legacy guidance written for the former Directives 93/42/EEC and 90/385/EEC. It is not MDR guidance. In 2026 it remains useful as a structural reference for the four-stage clinical evaluation process and for the discipline of literature appraisal, but wherever its text diverges from MDR Article 61, Annex XIV Part A, or MDCG 2020-5 (April 2020), the MDR text and the MDCG guidance win. Treat MEDDEV 2.7/1 Rev 4 as a historical scaffold to learn from, not as current binding interpretation.**

**By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.**

---

## TL;DR

- MEDDEV 2.7/1 Rev 4 (June 2016) was written under the MDD and AIMDD. The MDR entered application on 26 May 2021 and replaces those Directives. MEDDEV 2.7/1 Rev 4 has not been re-issued for the MDR.
- It is not superseded in full. Parts of its methodology — the four-stage process, literature search discipline, appraisal criteria, transparent data handling — remain the best plain-language description of how to actually run a clinical evaluation, and notified body reviewers still recognise its structure.
- It is partially superseded on equivalence. MDCG 2020-5 (April 2020) is the MDR-era authority on how technical, biological, and clinical equivalence are assessed. Any equivalence argument that uses the MEDDEV 2.7/1 Rev 4 approach without cross-checking MDCG 2020-5 will not survive review.
- MDR Article 61 and Annex XIV Part A override MEDDEV 2.7/1 Rev 4 wherever the two diverge. For implantable and Class III devices, MDCG 2023-7 (December 2023) further clarifies Article 61(4)-(6) on clinical investigation exemptions and "sufficient levels of access" to data.
- Auditors treat MEDDEV 2.7/1 Rev 4 as a familiar reference, not a compliance document. Citing it in a CER without also citing the current MDR text is a red flag. Citing both, with the MDR taking precedence, is normal practice.
- In 2026, the honest answer is: read it, learn the process discipline from it, then build your clinical evaluation against the MDR text and MDCG 2020-5.

---

## Why this question keeps coming up

Every few weeks a founder sends the same email. "Our consultant / our template / our previous regulatory affairs manager built the clinical evaluation around MEDDEV 2.7/1 Rev 4. Is that still valid under MDR, or do we have to throw it out?"

The question is reasonable. MEDDEV 2.7/1 Rev 4 is the document most people learned clinical evaluation from. It is detailed, plainly written, and codifies a four-stage process that has shaped CER practice across Europe for a decade. Throwing it out feels wasteful. Keeping it feels risky under a new Regulation. The honest answer sits between the two, and it matters for every CER being written in 2026.

This post walks through what MEDDEV 2.7/1 Rev 4 actually is, where the MDR has moved on from it, where MDCG 2020-5 explicitly replaces parts of it, what still applies methodologically, and how notified body reviewers treat the guidance in 2026.

## The origin of MEDDEV 2.7/1 Rev 4

MEDDEV 2.7/1 Rev 4 was published in June 2016 as "Guidelines on Medical Devices — Clinical Evaluation: A Guide for Manufacturers and Notified Bodies under Directives 93/42/EEC and 90/385/EEC." Revision 4 was a substantial rewrite of the previous Rev 3 from 2009. It added significantly more rigour to literature search methodology, introduced stricter appraisal criteria, tightened the expectations for equivalence, and expanded the guidance on post-market clinical follow-up.

It was written for the Directives, not the MDR. This is the first and most important fact about the document. At the time of publication, the MDR had already been drafted and was moving toward adoption — Regulation (EU) 2017/745 was adopted in April 2017 — but MEDDEV 2.7/1 Rev 4 refers to the Directives throughout. Every article number it cites is a Directive article number. Every requirement it describes is a Directive requirement. It was never re-issued for the MDR, and it has not been updated since June 2016.

In the transition years between 2017 and 2021, MEDDEV 2.7/1 Rev 4 was used by many manufacturers and notified bodies as the de facto clinical evaluation methodology, because it was the most detailed guidance available and the new MDR guidance ecosystem had not yet been built. That practice has left a long tail. CERs written during the transition often carry MEDDEV 2.7/1 Rev 4 as their primary reference, and the habit has persisted into 2026 even where the methodology should have moved on.

## What MEDDEV 2.7/1 Rev 4 actually covers

The document is organised around a four-stage clinical evaluation process that still maps recognisably onto the structure of MDR Annex XIV Part A Section 2, even though the vocabulary differs.

- **Stage 0 — Scope definition.** The clinical evaluation plan defines the questions the evaluation must answer: the intended purpose, the device description, the target population, the risks and benefits, the state of the art, and the acceptance criteria for the benefit-risk ratio.
- **Stage 1 — Identification of pertinent data.** A structured search of scientific literature, clinical experience with the device or equivalent devices, and any in-house clinical data. The search is documented, reproducible, and transparent.
- **Stage 2 — Appraisal of each dataset.** Each piece of data is assessed for methodological quality, relevance to the clinical evaluation questions, and contribution to the body of evidence. Appraisal criteria are pre-specified.
- **Stage 3 — Analysis of the clinical data.** The appraised data is synthesised against the clinical claims, the benefit-risk criteria, and the state of the art, and a conclusion is drawn on whether conformity with the relevant essential requirements is demonstrated.

Alongside the four stages, MEDDEV 2.7/1 Rev 4 contains detailed appendices on clinical evaluation report structure, literature search protocols, appraisal criteria, equivalence demonstration, and the qualification expectations for the clinical evaluator. Many of these appendices remain the clearest plain-language description of the mechanics of clinical evaluation that any European guidance has ever produced. That is why the document refuses to die.

## Where the MDR explicitly diverges

The MDR is stricter than the Directives on clinical evaluation in several specific, named ways. Wherever it is stricter, MEDDEV 2.7/1 Rev 4 is not a safe reference.

- **Authority of the plan.** MDR Annex XIV Part A Section 1(a) makes the clinical evaluation plan a mandatory, documented deliverable with a defined content list. MEDDEV 2.7/1 Rev 4 treats the plan as strongly recommended practice. Under MDR the plan is not optional.
- **Continuous lifecycle evaluation.** MDR Article 61(3) makes clinical evaluation an explicit lifecycle obligation updated with PMCF data, with annual CER updates mandated for Class III and implantable devices. MEDDEV 2.7/1 Rev 4 describes a looser update cadence.
- **Equivalence conditions.** MDR Annex XIV Part A Section 3 sets three equivalence characteristics — technical, biological, clinical — that must all be met to the extent that there would be no clinically significant difference in safety and clinical performance. MEDDEV 2.7/1 Rev 4 uses similar categories, but the MDR raises the bar, tightens the language, and adds specific conditions for implantable and Class III devices including contractual access to the equivalent device's technical documentation.
- **Clinical investigation default for implantable and Class III.** Article 61(4) establishes clinical investigations as the general rule for implantable and Class III devices, with narrow exemptions in 61(5) and 61(6) that MDCG 2023-7 (December 2023) clarifies further. MEDDEV 2.7/1 Rev 4, written under the Directives, does not reflect this default.
- **State of the art.** MDR Article 2(48) defines state of the art explicitly and makes it central to the benefit-risk analysis and equivalence assessment. MEDDEV 2.7/1 Rev 4 references the concept but without the definitional weight the MDR now places on it.

Each of these divergences is a place where a CER that leans on MEDDEV 2.7/1 Rev 4 without checking against the MDR text will generate findings at notified body review.

## Where MDCG 2020-5 explicitly supersedes it

MDCG 2020-5, "Clinical Evaluation — Equivalence: A guide for manufacturers and notified bodies" (April 2020), is the MDR-era successor to the equivalence sections of MEDDEV 2.7/1 Rev 4. It does not supersede the whole MEDDEV document. It supersedes the equivalence treatment specifically.

MDCG 2020-5 is explicit about the gap. It highlights differences between the MDR Annex XIV Part A Section 3 equivalence regime and the more permissive MEDDEV 2.7/1 Rev 4 approach, and it sets expectations for how manufacturers and notified bodies are to assess each of the three characteristics under the MDR. For implantable and Class III devices it works alongside MDCG 2023-7 on the "sufficient levels of access" to clinical data requirement.

The practical implication is simple. If your CER is making an equivalence argument, MDCG 2020-5 is the document you cite, not MEDDEV 2.7/1 Rev 4. If your CER cites MEDDEV 2.7/1 Rev 4 for equivalence without also citing MDCG 2020-5, it is behind by six years of MDR practice and the reviewer will treat it accordingly.

## What still applies methodologically

Stripping the Directive-specific content away, three things in MEDDEV 2.7/1 Rev 4 remain directly transferable to an MDR clinical evaluation in 2026.

- **The four-stage process discipline.** Scope, identification, appraisal, analysis. Each stage documented. Each stage traceable. This is how Annex XIV Part A Section 2 is actually executed in a CER, and MEDDEV 2.7/1 Rev 4 still describes the mechanics more clearly than any MDR-era document.
- **Literature search rigour.** The protocol-first, reproducible, documented literature search methodology in Appendix A5 of MEDDEV 2.7/1 Rev 4 is the best practical description of how to identify pertinent data under Annex XIV Part A. The MDR does not contradict it. It presupposes it.
- **Appraisal criteria pre-specification.** The expectation that inclusion and exclusion criteria, quality weightings, and relevance scoring are defined before the data is read — not retrofitted afterward — is one of the most valuable disciplines in the document and maps cleanly onto MDR practice. Reverse-engineered appraisal is the single most common finding in CER reviews.

A CER that uses MEDDEV 2.7/1 Rev 4 for these three things, while citing MDR Article 61, Annex XIV Part A, and MDCG 2020-5 for the substantive requirements, is a CER that has used the legacy document correctly.

## How notified body auditors treat MEDDEV 2.7/1 Rev 4 in 2026

From Tibor's work on both sides of the table — as a lead auditor and as the expert drafting CERs that get audited — the pattern in 2026 is consistent.

Notified body reviewers are familiar with MEDDEV 2.7/1 Rev 4. They trained on it. They still recognise its language and its structure. They do not automatically reject a CER that references it. What they look for is whether the CER also cites and applies the current MDR framework.

A CER that cites only MEDDEV 2.7/1 Rev 4 signals that the manufacturer has not updated their methodology since the Directives. That is a red flag, and reviewers dig harder. A CER that cites MEDDEV 2.7/1 Rev 4 as a structural reference for the four-stage process alongside MDR Article 61, Annex XIV Part A, and MDCG 2020-5 signals that the manufacturer understands the hierarchy: MDR text first, MDCG guidance second, legacy guidance as historical scaffold. That is normal practice and reviewers accept it.

The equivalence section is where most of the damage happens. A CER that makes an equivalence claim under the MEDDEV 2.7/1 Rev 4 logic without applying MDCG 2020-5 will be challenged at review. A CER that makes the same claim under MDCG 2020-5 and cross-references the MDR text will either pass or fail on the substance, not on the choice of reference.

## The Subtract to Ship angle

Subtract to Ship applied to legacy guidance is not about cutting MEDDEV 2.7/1 Rev 4 from your reading list. It is about cutting the parts of your CER that depend on it for requirements the MDR now sets directly.

Read MEDDEV 2.7/1 Rev 4 once, carefully, for the methodology. Then build the CER against the MDR text and MDCG 2020-5. When a section of your CER explains how literature was searched or how appraisal criteria were applied, MEDDEV 2.7/1 Rev 4 is a legitimate structural reference. When a section of your CER explains why equivalence is claimed, or why the clinical evaluation plan is structured the way it is, or why clinical investigation was or was not required, MEDDEV 2.7/1 Rev 4 is not the reference — MDR Article 61, Annex XIV Part A, MDCG 2020-5, and where applicable MDCG 2023-7 are.

The discipline is the same as every other Subtract to Ship pass. Trace every section of the CER to a specific current obligation. Keep the legacy guidance where it earns its place methodologically. Remove it where the MDR has moved on.

## Reality Check — Where do you stand?

1. Do you know which revision of MEDDEV 2.7/1 your current clinical evaluation references, and when that revision was written?
2. Does your clinical evaluation plan cite MDR Article 61 and Annex XIV Part A directly, or does it still route the requirements through MEDDEV 2.7/1 Rev 4?
3. If your CER makes an equivalence claim, does it cite MDCG 2020-5 (April 2020) as the authoritative interpretation, or does it rely on the MEDDEV 2.7/1 Rev 4 equivalence language?
4. If your device is implantable or Class III and claims equivalence, have you read MDCG 2023-7 and applied its "sufficient levels of access" clarification?
5. Is your literature search methodology transparent and reproducible in the way MEDDEV 2.7/1 Rev 4 Appendix A5 describes, even if the rest of your CER follows the MDR text directly?
6. Are your appraisal criteria pre-specified in the clinical evaluation plan, or were they invented after the data was read?
7. If a notified body reviewer picked up your CER tomorrow, would they see a document anchored in the current MDR framework with MEDDEV 2.7/1 Rev 4 used for methodology, or a document still living in the Directive era?

## Frequently Asked Questions

**Is MEDDEV 2.7/1 Rev 4 still valid under MDR in 2026?**
It is not current MDR guidance. It remains a legacy reference written for the former Directives 93/42/EEC and 90/385/EEC. Parts of its methodology — the four-stage process, literature search discipline, appraisal criteria — remain useful as structural references. Parts of its content — particularly the equivalence approach — have been superseded by MDR Annex XIV Part A Section 3 and MDCG 2020-5 (April 2020). Use it as methodology, not as authority.

**Has MEDDEV 2.7/1 been re-issued for the MDR?**
No. There is no MDR version of MEDDEV 2.7/1. Revision 4 from June 2016 is the last edition and was written under the Directives. Its MDR-era successor for equivalence specifically is MDCG 2020-5. For the overall clinical evaluation framework, the MDR text (Article 61 and Annex XIV) and the MDCG guidance ecosystem take its place.

**Can I still cite MEDDEV 2.7/1 Rev 4 in a CER?**
Yes, as a methodological reference for the four-stage process and literature appraisal discipline. No, as the sole authority for equivalence, clinical investigation requirements, or the clinical evaluation plan content. Best practice in 2026 is to cite the MDR text and MDCG 2020-5 as the primary references and MEDDEV 2.7/1 Rev 4 as a supporting methodological reference where relevant.

**What replaces MEDDEV 2.7/1 Rev 4 for equivalence under MDR?**
MDCG 2020-5 — Clinical Evaluation — Equivalence: A guide for manufacturers and notified bodies (April 2020). For implantable and Class III devices, MDCG 2023-7 (December 2023) clarifies the related "sufficient levels of access" requirement and the Article 61(4)-(6) clinical investigation exemptions.

**Will notified body auditors reject a CER that references MEDDEV 2.7/1 Rev 4?**
Not automatically. They will check whether the CER also applies the current MDR framework. A CER that uses MEDDEV 2.7/1 Rev 4 as a structural reference alongside MDR Article 61, Annex XIV Part A, and MDCG 2020-5 is normal practice. A CER that relies on MEDDEV 2.7/1 Rev 4 as the primary authority, without the MDR layer, signals that the methodology has not been updated and will generate findings.

**Does the MEDDEV 2.7/1 Rev 4 literature search methodology still apply under MDR?**
The methodology itself — protocol-first, documented, reproducible, with pre-specified inclusion and exclusion criteria — is directly consistent with MDR Annex XIV Part A Section 2 expectations. The MDR does not contradict it; it presupposes this kind of rigour. Using the MEDDEV 2.7/1 Rev 4 literature search structure while citing Annex XIV Part A as the underlying requirement is a defensible approach in 2026.

## Related reading

- [What Is Clinical Evaluation Under MDR?](/blog/what-is-clinical-evaluation-under-mdr) — the Cat 3 pillar post and the starting point for the whole clinical evaluation cluster.
- [MDR Annex XIV Part A: Clinical Evaluation Requirements](/blog/mdr-annex-xiv-part-a-clinical-evaluation) — the annex walkthrough that replaces the procedural sections of MEDDEV 2.7/1 Rev 4 under MDR.
- [MDR Article 61 Clinical Evaluation Requirements](/blog/mdr-article-61-clinical-evaluation-requirements) — the article-by-article walkthrough of the core clinical evaluation obligation.
- [The Clinical Evaluation Plan: What Annex XIV Part A Section 1 Requires](/blog/clinical-evaluation-plan-mdr) — the CEP deep-dive for the plan content the MDR now mandates.
- [Clinical Evaluation Report Structure Under MDR](/blog/clinical-evaluation-report-structure-mdr) — how to structure a CER that maps to Annex XIV Part A instead of the MEDDEV 2.7/1 Rev 4 outline.
- [Literature Review for MDR Clinical Evaluation](/blog/literature-review-mdr-clinical-evaluation) — the search methodology where MEDDEV 2.7/1 Rev 4 discipline still pays off.
- [Equivalence Under MDR](/blog/equivalence-under-mdr) — the dedicated deep-dive on Annex XIV Part A Section 3 and MDCG 2020-5.
- [How to Read the MDR: A Practical Guide for Founders](/blog/how-to-read-the-mdr) — the meta-skill for working with the Regulation directly instead of through legacy guidance.
- [The Subtract to Ship Framework for MDR Compliance](/blog/subtract-to-ship-framework-mdr) — the methodology pillar and the Evidence Pass that governs how legacy guidance is applied in a lean CER.

## Sources

1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Article 61 (clinical evaluation), Annex XIV Part A (clinical evaluation), Annex XIV Part A Section 3 (equivalence conditions). Official Journal L 117, 5.5.2017.
2. MEDDEV 2.7/1 revision 4 — Clinical Evaluation: A Guide for Manufacturers and Notified Bodies under Directives 93/42/EEC and 90/385/EEC, June 2016 (legacy guidance written for the former Directives; not re-issued for the MDR).
3. MDCG 2020-5 — Clinical Evaluation — Equivalence: A guide for manufacturers and notified bodies, April 2020 (the MDR-era successor for equivalence specifically).
4. MDCG 2023-7 — Guidance on exemptions from the requirement to perform clinical investigations pursuant to Article 61(4)-(6) MDR and on 'sufficient levels of access' to data needed to justify claims of equivalence, December 2023.

---

*This post is part of the Clinical Evaluation & Clinical Investigations cluster in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. MEDDEV 2.7/1 Rev 4 is the document most of us learned clinical evaluation from, and in 2026 the honest thing to do is keep what taught us the process discipline and let the MDR text and MDCG 2020-5 take over the rest.*

---

*This post is part of the [Clinical Evaluation & Investigations](https://zechmeister-solutions.com/en/blog/category/clinical-evaluation) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*